Recurrent mutations in RAS signaling pathway genes (NRAS, KRAS, PIK3CD, and PTPN11) have been identified in TCF3-ZNF384-rearranged B-ALL [59], and this may explain at least partly the aggressive clinical course of this B-ALL subtype. This evidence concerns the gene NRAS and acute lymphoblastic leukemia.